Novartis Wins Landmark Case Against German Government Over Desloratadine Switch
Generics giant Novartis through its Hexal subsidiary has won an important case against the German Ministry of Health over a delayed prescription-to-OTC switch of desloratadine, which shows European Union Member States have got the authority to switch at a national level centrally authorized drugs.
You may also be interested in...
OTC marketing news from Germany: A hard-won desloratadine launch from Novartis, two new products from Dermapharm, as well as homeopathic and probiotic alternatives from Hevert and Bencard.
Following a landmark win against the German government for the Rx-to-OTC switch of desloratadine last month, Novartis has again secured a victory in the German Higher Court system, this time to continue marketing its Biosan probiotics range in the country.
Just under 50% of Germans and 65% of German migraine sufferers would like to see more migraine medicines available OTC, according to a survey commissioned by the German Association of Pharmaceutical Manufacturers (BAH).